Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon vs placebo for pediatric insomnia disorder
2024-516411-24-00Phase 3Authorised
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing Tasimelteon with Placebo (2 arms). Primary endpoint: Sleep as measured by daily sleep diary. Planned start Feb 2026; status: authorised.
02
Drugs
tasimelteon
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2024-516411-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516411-24-00.